



DeanHealthPlan[®]

A member of SSM Health

Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

**Inflammatory Bowel Disease: Serologic Markers,
Fecal Calprotectin, and Diagnostic Testing**

MP9533

Covered Service: Yes

**Prior Authorization
Required:** No

**Additional
Information:** For fecal analysis testing, see [Fecal Analysis in the Diagnosis of Intestinal Disorders MP9515](#)

Medicare Policy: Prior authorization is dependent on the member's Medicare coverage. Prior authorization is not required for Dean Care Gold and Select when this service is provided by participating providers. If a member has Medicare primary and Dean Health Plan as secondary coverage, a prior authorization is required.

**BadgerCare Plus
Policy:** Dean Health Plan covers when BadgerCare Plus also covers the benefit.

Dean Health Plan Medical Policy:

- 1.0 The following serological markers which are intended to diagnose or manage inflammatory bowel disease or irritable bowel syndrome, **OR** to differentiate Ulcerative Colitis from Crohn's disease, are considered experimental and investigational (not an all-inclusive list):
 - 1.1 Anti-chitobioside carbohydrate antibodies (ACCA),
 - 1.2 Anti-smooth muscle antibodies (ASMA),
 - 1.3 Anti-laminaribioside carbohydrate antibodies (ALCA),
 - 1.4 Anti-mannobioside carbohydrate antibodies (AMCA),
 - 1.5 Anti-chitin IgA (Anti-C), and
 - 1.6 Anti-laminarin IgA (Anti-L),
 - 1.7 Anti-neutrophil cytoplasmic antibodies (pANCA),
 - 1.8 Anti-Saccharomyces cerevisiae antibodies (ASCA),
 - 1.9 Anti-outer membrane porin C (anti-OmpC) antibodies,
 - 1.10 Anti-CBir1 flagellin (anti-CBir1) antibodies,



DeanHealthPlan®

A member of SSM Health

Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

- 1.11 Pseudomonas fluorescens (Anti-I2) antibodies
- 2.0 Fecal measurement of calprotectin **does not** require prior authorization and is considered medically necessary for the following indications:
 - 2.1 Differentiating inflammatory bowel diseases (e.g. Crohn's disease, ulcerative colitis) and for distinguishing inflammatory bowel disease from irritable bowel syndrome in individuals with symptoms that have lasted greater than four (4) weeks, **OR**
 - 2.2 Monitoring/managing disease activity in inflammatory bowel disease
 - 2.3 Fecal measurement of calprotectin for all other indications is considered experimental and investigational, and therefore not medically necessary.
- 3.0 The following tests are considered experimental and investigational, and therefore not medically necessary:
 - 3.1 Centrosomal protein 72 (*CEP72*) gene testing
 - 3.2 Crohn's disease peptide antibody testing
 - 3.3 ECM1 and Stat-3 testing for ulcerative colitis
 - 3.4 eXaIBD test (a quantitative PCR test for 6 genes [BLCAP, UBE2G1, GPX1, RAP1A, CALM3 and NONO]),
 - 3.5 *Firmicutes and Bacteroidetes* (F/B) ratio stool test (e.g. Salveo Diagnostics)
 - 3.6 IBSDetex test for irritable bowel syndrome
 - 3.7 Measurements of DNA, mRNA and protein biomarkers for predicting therapeutic response in inflammatory bowel disease
 - 3.8 Measurement of serum mannose-binding lectin
 - 3.9 Myeloperoxidase antibody testing for inflammatory bowel disease
 - 3.10 Proteinase-3 antibody testing
 - 3.11 Raman spectroscopy for inflammatory bowel disease
 - 3.12 Serum amyloid A as a biomarker of disease activity in Crohn's disease
 - 3.13 Whole blood gene expression analysis in the evaluation of Crohn's disease and ulcerative colitis (e.g. PredictSURE IBD).



DeanHealthPlan[®]

A member of SSM Health

Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Quality and Care Management Division	August 15, 2018
Revised:	Medical Policy Committee/Health Services Division	July 17, 2019
	Medical Policy Committee/Health Services Division	July 15, 2020
	Medical Policy Committee/Health Services Division	July 21, 2021
	Medical Policy Committee/Health Services Division	July 20, 2022
	Medical Policy Committee/Health Services Division	February 15, 2023
Reviewed:	Medical Policy Committee/Health Services Division	July 17, 2019
	Medical Policy Committee/Health Services Division	July 15, 2020
	Medical Policy Committee/Health Services Division	July 21, 2021
	Medical Policy Committee/Health Services Division	July 20, 2022
	Medical Policy Committee/Health Services Division	February 15, 2023

Published: 03/01/2023

Effective: 03/01/2023